Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression

Medical Care

Volumn 42, Issue 12, 2004, Pages 1176-1185

  Donohue, Julie M ^a,e   Berndt, Ernst R ^b   Rosenthal, Meredith ^c   Epstein, Arnold M ^c   Frank, Richard G ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antidepressants; Depression; Detailing; Direct to consumer advertising; Pharmaceutical promotion

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADVERTIZING; ARTICLE; DEPRESSION; DRUG USE; DRUG UTILIZATION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE;

EID: 10344262548     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200412000-00004     Document Type: Article

References (45)

1. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 study. JAMA. 1995;274:1511-1517.
2. Ormel J, VonKorff M, Ustun TB, et al. Common mental disorders and disability across cultures: results from the WHO collaborative study on psychological problems in general health care. JAMA 1994;272:1741-1748.
3. Mental Health: A Report of the Surgeon General. Washington, DC: US Department of Health & Human Services; December 1999.
4. Depression Guideline Panel. Depression in Primary Care: Treatment of Major Depression. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1993. Available at http://www.mentalhealth.com/bookah/p44-d2.html. Accessed October 6, 2004.
5. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depression. Available at http://www.psych.org/psych_pract/ treatg/pg/Depression2e.book.cfm. Accessed September 10, 2004.
6. Schulberg HC, Katon W, Simon GE, et al. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry. 1998;55:1121-1127.
7. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
8. Young AS, Klap R, Sherbourne CD, et al. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry. 2001;58:55-61.
9. Hirschfeld RM, Keller MB, Panico S. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333-340.
10. Wells KB, Katon W, Rogers B, et al. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the medical outcomes study. Am J Psychiatry. 1994;151:694-700.
11. Fortney J, Rost K, Zhang M, et al. The relationship between quality and outcomes in routine depression care. Psychiatr Serv. 2001;52:56-62.
12. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128-1132.
13. Regier DA, Hirschfeld RMA, Goodwin FK, et al. The NIMH Depression Awareness, Recognition and Treatment Program: structure, aims and scientific basis. Am J Psychiatry. 1988;145:1351-1357.
14. Unutzer J, Rubenstein L, Katon WJ, et al. Two-year effects of quality improvement programs on medication management for depression. Arch Gen Psychiatry. 2001;58:935-942.
15. Sherbourne CD, Wells KB, Duan N, et al. Long-term effectiveness of disseminating quality improvement for depression in primary care. Arch Gen Psychiatry. 2001;58:696-703.
16. Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care. JAMA. 2000;283:212-220.
17. O'Hara MW, Gorman LL, Wright EJ. Description and evaluation of the Iowa Depression Awareness, Recognition and Treatment Program. Am J Psychiatry. 1996;153:645-649.
18. Wosinska M. Promoting to Multiple Agents: The Case of Direct-to-Consumer Drug Advertising [PhD dissertation]. Berkeley, CA: UC Berkeley, Department of Economics; 2002.
19. Rizzo JA. Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs. J Law Econ. 1999;42:89-116.
20. Berndt ER, Bui LT, Reiley DHL, et al. Information, marketing and pricing in the U.S. anti-ulcer drug market. Am Econ Rev. 1995;85:100-105.
21. Wolfe SM. Direct-to-consumer advertising - education or emotion promotion? N Engl J Med. 2002;346:524-526.
22. Hollon MF. Direct-to-consumer marketing of prescription drugs. JAMA. 1999;281:382-384.
23. Holmer AF. Direct-to-consumer advertising - strengthening our health care system. N Engl J Med. 2002;346:526-528.
24. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999;281:380-382.
25. Donohue JM, Berndt ER. Direct-to-consumer advertising and choice of antidepressant. J Pub Pol Marketing. 2004. In Press.
26. Deleted in proof.
27. International survey on wellness and consumer reaction to DTC advertising of prescription drugs. Prevention Magazine 2001;46-55.
28. Kaiser Public Opinion Update. The Public and Prescription Drugs. September 2000. Available at http://kff.org/rxdrugs/. Accessed October 6, 2004.
29. Attitudes and Behaviors Associated with Direct-to-Consumer Promotion of Prescription Drugs. Rockville, MD: Office of Medical Policy, Division of Drug Marketing, Advertising and Communications, Center for Drug Evaluation and Research, US Food and Drug Administration; 2001.
30. Weissman JS, Blumenthal D, Silk AJ, et al. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Affairs (online journal; February 2003; web only). Available at http://content.healthaffairs. org/webexclusive/index.dtl?year=2003. Accessed October 6, 2004.
31. Melfi CA, Croghan TW. Use of claims data for research on treatment and outcomes of depression care. Med Care 1999;37(4 Lilly Suppl): AS77-AS80.
32. Streator SE, Moss JT. Identification of off-label antidepressant use and costs in a network model HMO. Drug Benefit Trends 1997;9:42, 48-49, 50, 55-56.
33. Ling DC, Berndt ER, Kyle MK. Deregulating direct-to-consumer marketing of prescription drugs: effects on prescription and over-the-counter product sales. J Law Econ. 2002;45:691-723.
34. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
35. Katon W, Rutter C, Ludman E, et al. A randomized trial of relapse prevention of depression in primary care. Arch Gen Psych. 2001;58: 241-247.
36. Peveler R, George C, Kinmonth AL, et al. Effect of antidepressant drug counseling and information leaflets on adherence to drug treatment in primary care: randomized controlled trial. BMJ. 1999;319:612-615.
37. Loden J, Schooler C. Patient compliance. Pharmaceutical Executive. 2000;20:88-94.
38. Brichacek A. DTC strategies target compliance. Pharmaceutical Executive. 2000;20:74-75.
39. Soumerai SB, Avorn J. Predictors of physician prescribing change in an educational experiment to improve medication use. Med Care. 1987;25: 210-221.
40. Soumerai SB, Avorn J. Principles of educational outreach ("academic detailing") to improve clinical decision making. JAMA. 1990;263:549-556.
41. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995;273:1296-1298.
42. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can Fam Phys. 1997;43:941-945.
43. Broadhead WE. Misdiagnosis of depression: physicians contribute to the stigmatization of mental illness. Arch Fam Med. 1994;3:319.
44. Rost K, Smith GR, Matthews DB, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med. 1994;3:333.
45. Browne RA, Melfi CA, Croghan TW, et al. Data issues to consider when conducting research using physician-reported antidepressant claims. Drug Benefit Trends. 1998;10:37.